Health Canada drug identification number

DIN 02522160 — ABEVMY 400 MG

ABEVMY is a solution of Bevacizumab marketed by BIOCON BIOLOGICS CANADA INC. The full Bevacizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.

DIN
02522160
Brand name
ABEVMY
Active ingredient
Bevacizumab
Strength
400 MG
Dosage form
SOLUTION
Route
INTRAVENOUS
Manufacturer
BIOCON BIOLOGICS CANADA INC
Health Canada status
MARKETED
Drug class
Vascular endothelial growth factor (VEGF) inhibitor (monoclonal antibody, antineoplastic agent)

Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.

Other Bevacizumab products

DINBrandStrengthFormManufacturerStatus
02522179 ABEVMY 100 MG SOLUTION BIOCON BIOLOGICS CANADA INC MARKETED
02270994 AVASTIN 25 MG SOLUTION HOFFMANN-LA ROCHE LIMITED MARKETED
02522829 AYBINTIO 100 MG SOLUTION SAMSUNG BIOEPIS CO., LTD MARKETED
02522837 AYBINTIO 400 MG SOLUTION SAMSUNG BIOEPIS CO., LTD MARKETED
02520729 BAMBEVI 100 MG SOLUTION APOTEX INC MARKETED
02520737 BAMBEVI 400 MG SOLUTION APOTEX INC MARKETED
02470748 MVASI 25 MG SOLUTION AMGEN CANADA INC MARKETED
02470756 MVASI 25 MG SOLUTION AMGEN CANADA INC MARKETED
02534177 VEGZELMA 100 MG SOLUTION CELLTRION INC. MARKETED
02534185 VEGZELMA 400 MG SOLUTION CELLTRION INC. MARKETED
02489430 ZIRABEV 100 MG SOLUTION PFIZER CANADA ULC MARKETED
02489449 ZIRABEV 400 MG SOLUTION PFIZER CANADA ULC MARKETED

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.